References

Heart failure with preserved ejection fraction

10.1056/nejmcp2305181 · 2025 · External reference

Prevalence and incidence of heart failure in type 2 diabetes patients: results from a nationwide prospective cohort—the DIABET-IC study

10.1186/s12933-024-02358-0 · 2024 · External reference

Empagliflozin in heart failure with a preserved ejection fraction

10.1056/nejmoa2107038 · 2021 · External reference

Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction

10.1056/nejmoa2206286 · 2022 · External reference

Finerenone in heart failure with mildly reduced or preserved ejection fraction

10.1056/nejmoa2407107 · 2024 · External reference

Tirzepatide for heart failure with preserved ejection fraction and obesity

10.1056/nejmoa2410027 · 2024 · External reference

An evidence-based screening tool for heart failure with preserved ejection fraction: the HFpEF-ABA score

10.1038/s41591-024-03140-1 · 2024 · External reference

Characteristics of women with type 2 diabetes mellitus and heart failure in Spain. The DIABET-IC study

10.5603/cj.a2023.0016 · 2024 · External reference

Sex differences in the diagnosis and management of heart failure among outpatients with type 2 diabetes

10.1177/15409996251401741 · 2026 · External reference

Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American society of echocardiography and the European association of cardiovascular imaging

10.1093/ehjci/jew082 · 2016 · External reference

Guidelines for performing a comprehensive transthoracic echocardiographic examination in adults: recommendations from the American Society of Echocardiography

10.1016/j.echo.2018.06.004 · 2019 · External reference

2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure

10.1093/eurheartj/ehw128 · 2016 · External reference

Use and misuse of composite endpoints in randomised clinical trials

2025 · External reference

Cardiometabolic heart failure with preserved ejection fraction: from molecular signatures to personalized treatment

10.1186/s12933-025-02774-w · 2025 · External reference

Interplay of chronic kidney disease and the effects of tirzepatide in patients with heart failure, preserved ejection fraction, and obesity: the SUMMIT trial

10.1016/j.jacc.2025.03.009 · 2025 · External reference

Temporal prevalence and prognostic impact of diabetes mellitus and albuminuria in heart failure with preserved ejection fraction

10.1186/s12933-025-02708-6 · 2025 · External reference

Metabolic rewiring and inter-organ crosstalk in diabetic HFpEF

10.1186/s12933-025-02707-7 · 2025 · External reference

Heart failure with preserved ejection fraction: JACC scientific statement

10.1016/j.jacc.2023.01.049 · 2023 · External reference

Circulating mediators linking cardiometabolic diseases to HFpEF: a mediation Mendelian randomization analysis

10.1186/s12933-025-02738-0 · 2025 · External reference

Sex-specific cardiometabolic multimorbidity, metabolic syndrome and left ventricular function in heart failure with preserved ejection fraction in the UK biobank

10.1186/s12933-025-02788-4 · 2025 · External reference

Haemodynamics, dyspnoea, and pulmonary reserve in heart failure with preserved ejection fraction

10.1093/eurheartj/ehy268 · 2018 · External reference

Comprehensive exploration of unexplained dyspnoea in subjects with normal ejection fraction and low natriuretic peptides

10.1002/ehf2.15059 · 2025 · External reference

Uncovering unrecognized heart failure with preserved ejection fraction among individuals with obesity and dyspnea

10.1161/circheartfailure.123.011366 · 2024 · External reference

Evidence-based application of natriuretic peptides in the evaluation of chronic heart failure with preserved ejection fraction in the ambulatory outpatient setting

10.1161/circulationaha.124.072156 · 2025 · External reference

Body mass index, natriuretic peptides, and risk of adverse outcomes in patients with heart failure and preserved ejection fraction: analysis from the TOPCAT trial

10.1161/jaha.118.009664 · 2018 · External reference

The influence of body mass index on clinical interpretation of established and novel biomarkers in acute heart failure

10.1016/j.cardfail.2023.03.029 · 2023 · External reference

Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations

10.1002/ejhf.1494 · 2019 · External reference

Obesity and natriuretic peptides, BNP and NT-proBNP: mechanisms and diagnostic implications for heart failure

10.1016/j.ijcard.2014.08.007 · 2014 · External reference

New algorithm for estimating left ventricular filling pressure by echocardiography

10.1161/circulationaha.125.074974 · 2025 · External reference

Heart failure with preserved ejection fraction: recent concepts in diagnosis, mechanisms and management

10.1136/heartjnl-2021-319605 · 2022 · External reference

10.1002/ejhf.2601

10.1002/ejhf.2601 · 2022 · External reference

Haemodynamic validation of the three-step HFA-PEFF algorithm to diagnose heart failure with preserved ejection fraction

10.1002/ehf2.14436 · 2023 · External reference

How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)

10.1093/eurheartj/ehz641 · 2019 · External reference

Heart failure with preserved ejection fraction: everything the clinician needs to know

10.1016/s0140-6736(23)02756-3 · 2024 · External reference

Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association

10.1161/cir.0000000000001184 · 2023 · External reference

Semaglutide in obesity-related heart failure with preserved ejection fraction and type 2 diabetes across baseline HbA1c levels (STEP-HFpEF DM): a prespecified analysis of heart failure and metabolic outcomes from a randomised, placebo-controlled trial

10.1016/s2213-8587(24)00304-8 · 2025 · External reference

Time to screen: rationale and roadmap for HFpEF screening in individuals with obesity

10.1007/s10741-025-10540-z · 2025 · External reference

Clinical implications of pretest probability of HFpEF on outcomes in precapillary pulmonary hypertension

10.1016/j.jacc.2024.08.061 · 2024 · External reference

Comparison of the 2021 ESC guideline with the HFA-PEFF and H2FPEF scores in diagnosing heart failure with preserved ejection fraction

10.1038/s41598-025-01537-7 · 2025 · External reference

A simple, evidence-based approach to help guide diagnosis of heart failure with preserved ejection fraction

10.1161/circulationaha.118.034646 · 2018 · External reference